Last reviewed · How we verify
VC004 Capsules
VC004 Capsules is a small molecule drug that targets the SGLT2 receptor.
VC004 Capsules is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | VC004 Capsules |
|---|---|
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the SGLT2 receptor, VC004 Capsules reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors (PHASE3)
- A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects (PHASE1)
- Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects (PHASE1)
- The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VC004 Capsules CI brief — competitive landscape report
- VC004 Capsules updates RSS · CI watch RSS
- Jiangsu vcare pharmaceutical technology co., LTD portfolio CI